External Awards Program
The External Awards Program provides funding for investigator-initiated clinical, pre-clinical, and early-stage research projects through a competitive peer-reviewed application process.
The program has two tracks. The Clinical Indication Track is geared primarily towards preclinical and first-in-human clinical studies.
The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research.
The External Awards Program provides funding for investigator-initiated research projects in the form of one-year awards totaling approximately $100,000, paid out in three or more installments tied to progress reports throughout the term of the project. Clinical, pre-clinical, and early-stage projects can be funded through one of the program’s two submission tracks. This program typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment. Exceptions to these guiding principles may be considered if the project addresses a gating factor in the near-term development of a reimbursable clinical application.
This research funding mechanism is driven by a two-step investigator application submitted online. A one-page Research Abstract (step 1) must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1). The Foundation will invite full Research Proposals (step 2) from authors of approved Research Abstracts. The Research Proposals are sent for external peer-review. Funding decisions (fund, revise, or reject) are returned to the applicant approximately three months after their application deadline. In general, investigators from whom revisions are requested will have only one opportunity to address reviewer comments before a final decision (fund or reject) is made.
The investigator must choose one of two tracks when crafting his or her Research Abstract: the Clinical Indication Track or the High-Risk Track.
The Clinical Indication Track is geared primarily towards preclinical and first-in-human clinical studies. It is meant to fund research projects that target a specific clinical indication and that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.
The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.
Clinical Indication Track